The impact of body weight on ovarian cancer outcomes
- PMID: 21997171
- PMCID: PMC4175395
- DOI: 10.1097/IGC.0b013e31822d2aa3
The impact of body weight on ovarian cancer outcomes
Abstract
Background: Obesity is a known risk factor and poor prognostic factor for many comorbidities including cancer. However, the influence of body mass index (BMI) on ovarian cancer outcomes is inconclusive. Therefore, the objective of this study was to evaluate the impact of BMI and weight changes on survival in patients with advanced ovarian cancer after primary treatment.
Methods: All patients with a diagnosis of advanced epithelial ovarian cancer from January 2000 to December 2007 undergoing primary cytoreductive surgery and adjuvant chemotherapy were identified. Patients were divided into 3 categories: underweight/normal weight (BMI, <25 kg/m), overweight (BMI, 25-30 kg/m), and obese (BMI, >30 kg/m). Adjusted hazard ratios for progression-free survival (PFS) and overall survival (OS) were calculated via Cox proportional hazards models.
Results: One hundred ninety-eight patients met the inclusion criteria. For all patients, the mean BMI was 26 kg/m (range, 16.4-49.1 kg/m), with 43% of patients being classified as normal weight, 29% overweight, and 28% as obese. Median 5-year OS was 48.2 months (95% confidence interval, 16.4-49.1 months), and no differences in OS were noted between BMI groups. Unadjusted median PFS for patients with normal weight was 13.7 months, compared with 15.5 and 17.9 months for the overweight and obese groups. Adjusted analysis of BMI over time indicates a trend of increased risk for patients who gain weight in the 6 months after primary therapy on disease progression (hazard ratio, 1.68; 95% confidence interval, 0.87-3.26).
Conclusions: After adjustment for confounders, such as stage, grade, histology, age, and debulking status, data suggest a trend toward a shorter PFS in patients with a normal BMI. However, OS was not significantly related to BMI, and weight change in the 6 months after completion of treatment had no effect on PFS or OS. Further research should be directed at elucidating relationships between weight and cancer biology.
Similar articles
-
Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.Support Care Cancer. 2017 Mar;25(3):795-800. doi: 10.1007/s00520-016-3462-1. Epub 2016 Oct 22. Support Care Cancer. 2017. PMID: 27771784
-
Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.Gynecol Oncol. 2015 Aug;138(2):263-6. doi: 10.1016/j.ygyno.2015.05.035. Epub 2015 May 30. Gynecol Oncol. 2015. PMID: 26037901
-
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.Gynecol Oncol. 2013 Dec;131(3):531-4. doi: 10.1016/j.ygyno.2013.09.030. Epub 2013 Oct 4. Gynecol Oncol. 2013. PMID: 24096109
-
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.Updates Surg. 2014 Jun;66(2):109-13. doi: 10.1007/s13304-013-0229-9. Epub 2013 Aug 27. Updates Surg. 2014. PMID: 23980020 Review.
-
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Clin Transl Oncol. 2011. PMID: 21324801 Review.
Cited by
-
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.Int J Gynecol Cancer. 2014 May;24(4):670-5. doi: 10.1097/IGC.0000000000000109. Int J Gynecol Cancer. 2014. PMID: 24614825 Free PMC article.
-
Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers.Sci Rep. 2025 Jul 1;15(1):21828. doi: 10.1038/s41598-025-09393-1. Sci Rep. 2025. PMID: 40595354 Free PMC article.
-
The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial.J Clin Med. 2022 Sep 29;11(19):5785. doi: 10.3390/jcm11195785. J Clin Med. 2022. PMID: 36233653 Free PMC article.
-
Dynamic Changes in Body Composition and Protein Intake in Epithelial Ovarian Cancer Patients Undergoing Chemotherapy: A Preliminary Study.Asian Pac J Cancer Prev. 2024 Feb 1;25(2):555-562. doi: 10.31557/APJCP.2024.25.2.555. Asian Pac J Cancer Prev. 2024. PMID: 38415542 Free PMC article.
-
The Impact of Preoperative Low Body Mass Index on Postoperative Complications and Long-term Survival Outcomes in Gastric Cancer Patients.J Gastric Cancer. 2018 Sep;18(3):274-286. doi: 10.5230/jgc.2018.18.e30. Epub 2018 Sep 14. J Gastric Cancer. 2018. PMID: 30276004 Free PMC article.
References
-
- Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004;291:2847–2850. - PubMed
-
- Rapp K, Klenk J, Ulmer H, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol. 2008;19(4):641–648. - PubMed
-
- Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79. - PubMed
-
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. - PubMed
-
- Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43:690–709. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous